Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 7, Issue 10, pp. 1633-1646
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 22, 2018
- Revision received March 5, 2019
- Accepted August 13, 2019
- Published first August 20, 2019.
Article Versions
- Previous version (August 20, 2019 - 06:23).
- Previous version (September 13, 2019 - 05:46).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Tatiana Pazina1,2,
- Ashley M. James1,
- Kimberly B. Colby1,
- Yibin Yang1,
- Andrew Gale1,
- Amy Jhatakia3,
- Alper Y. Kearney3,
- Robert F. Graziano3,
- Natalie A. Bezman3,
- Michael D. Robbins3,
- Adam D. Cohen4,*, and
- Kerry S. Campbell1,*
- 1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
- 2FSBSI “Institute of Experimental Medicine,” St. Petersburg, Russia.
- 3Bristol-Myers Squibb, Princeton, New Jersey.
- 4Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
- ↵*Corresponding Authors:
Kerry S. Campbell, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-7761; Fax: 215-728-2412; E-mail: kerry.campbell{at}fccc.edu; and Adam D. Cohen, Abramson Cancer Center at the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104. Phone: 215-615-5853; E-mail: adam.cohen{at}uphs.upenn.edu
October 2019
Volume 7, Issue 10
Volume 7, Issue 10
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
Jump to section
Advertisement